Tinea Pedis also called as Athlete’s foot is a superficial fungal infection of the feet caused by group of fungi known as dermatophytes. Fungi are eukaryotic organisms that live as saprophytes or parasites in two different forms as yeast and molds. Moist, occlusive environment is the ideal environment for the growth of such organism affecting keratin of the top layer of the epidermis. Conditions such as diabetes and HIV interfere with body’s immune system and increase the risk of getting infected with tinea pedis. The disease in more prevalent in the tropic and subtropical countries of the world. FDA reports Trichophyton rubrum as the main causative agent of Tinea pedis followed by Trichophyton mentagrophytes and Epidermophyton floccosum. However, microsporum canis, Trichophyton tonsurans and other dermatophyte species. Tinea pedis is estimated to affect 40% of the total population. The diseases are caused by dermatophyte infection. Clinical diagnosis of tinea pedis includes visualization of the fissure, maceration, and scaling in the interdigital or subdigital area of the feet. This may be the case for the first time. Tinea pedis is contagious and spreads through direct contact. Topical therapy is effective for the treatment of tinea pedis. General, the diseases can be treated using topical antifungals. However, patients with moccasin, vesicular tinea pedis, or persistent tinea pedis may require oral antifungal treatment.
Tinea pedis treatment market is expected to grow at a healthy pace at the same time as patients with concomitant diabetes, atopy, and immunosuppression. With a wide range of immunocompromised patients, tinea is an important cause of the disease.
Tinea Pedis Treatment Market: Drivers and Restraints
Skin conditions represents one of the most common health related problems affecting millions of people worldwide. The diseases are found in many different forms. Shoes, showers, and pool areas are frequent culprits that foster and spread tinea pedis infections. In addition, growing incidence of diabetes is the most important factor in the development of tinea pedis. It has been reported that 50% of the diabetic patients are at risk of developing tinea pedis at some point in their lifetime than non-diabetic patients. Tinea pedis treatment market is dominated by generics hence, big market players in the absence of any patent protection, face stiff competition from generics, leading to declining sales. Majority of products for topical treatment of tinea pedis have a moderate efficacy with extended treatment time. Therefore, it is important to note that this is not the case.
Request Free Report Sample @ http://www.futuremarketinsights.com/reports/sample/rep-gb-2084
Tinea Pedis Treatment Market: Segmentation
The global tinea pedis treatment market has been classified on the basis of type, traetment, end user and geography.
Based on type, the global tinea pedis treatment market is divided into the following:
- Interdigital Tinea Pedis
- Plantar Tinea Pedis
- Vesicular tinea pedis
Based on the treatment, the global tinea pedis treatment market is divided into the following:
- Topical Drugs
- gel
- Creams
- spray
- Lotions
- powder
- Oral Drugs
Based on the distribution channel, the global tinea pedis treatment market is divided into the following:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
Request For TOC @ http://www.futuremarketinsights.com/toc/rep-gb-2084
Tinea Pedis Treatment Market: Overview
Tinea pedis is a growing concern in many underdeveloped and developed countries. Lack of awareness and loss of the patient. The condition is widespread with a high rate of recurrence. Aging population and increasing prevalence of diabetic patients. However, the market for tinea pedis is a great opportunity for drug development. So, in the market, there is a huge market opportunity for tinea pedis treatment market in the near future.
Tinea Pedis Treatment Market: Regional Overview
Region North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa . R & D and increased FDA approvals are expected to be in line with the revenue traction in North America. Worldwide market for tinea pedis treatment is still evolving due to the dominance of generics and major drug development firms and different companies.
Smart Contact Lens: Key Players
Johnson & Johnson Services, Inc., Hisamitsu Pharmaceutical Co., Inc., Merck & Co. Inc., Novartis Ltd., Sanofi F. Hoffmann-La Roche Ltd, Beckman Coulter Inc., Kaken Pharmaceutical Co., Nitric BioTherapeutics, and Topica Pharmaceuticals.
Browse Full Report @ http://www.futuremarketinsights.com/reports/tinea-pedis-treatment-market